CAS
ATNM icon

Coppell Advisory Solutions’s Actinium Pharmaceuticals ATNM Stock Holding History

Coppell Advisory Solutions’s Portfolio ATNM Stock Details ATNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		$36 Buy
+7
New +$36 ﹤0.01% 1686
2023
Q3 		– Sell
-7
Closed -$50 – 1225
2023
Q2 		$50 Buy
+7
New +$60 ﹤0.01% 1397

Other funds holding ATNM

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BGIM
Brandywine Global Investment Management Philadelphia, Pennsylvania $14.9B AUM 20.41% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Coppell Advisory Solutions's ATNM Position: Q4 2023 in Review

Coppell Advisory Solutions opened a new position in Actinium Pharmaceuticals (ATNM) in Q4 2023: 7 shares worth $36. The stake represents ﹤0.01% of the portfolio and ranks #1686 among its holdings. This is a return to the name: Coppell Advisory Solutions previously reported a position in ATNM as recently as Q2 2023.

Coppell Advisory Solutions first reported a position in ATNM in Q2 2023 and has held it in 2 quarters since. The position peaked at $50 in Q2 2023. 59 funds tracked by Wall St. Rank hold ATNM as of Q4 2023.

  • Coppell Advisory Solutions held 7 shares of Actinium Pharmaceuticals worth $36 as of Q4 2023.
  • Actinium Pharmaceuticals was a new Coppell Advisory Solutions position in Q4 2023.
  • Actinium Pharmaceuticals made up ﹤0.01% of Coppell Advisory Solutions's portfolio in Q4 2023, its #1686 holding.
  • Coppell Advisory Solutions first reported a position in Actinium Pharmaceuticals in Q2 2023 and has held it in 2 quarters since.
  • Coppell Advisory Solutions's Actinium Pharmaceuticals position peaked at $50 in Q2 2023.
  • 59 funds tracked by Wall St. Rank held Actinium Pharmaceuticals as of Q4 2023.

Based on Coppell Advisory Solutions's 13F filing for Q4 2023, filed 14 Feb 2024.